Drug Profile


Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; Folotyn; PDX

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
  • Developer Allos Therapeutics; Columbia University; Mundipharma International; Rafa Laboratories
  • Class Antineoplastics; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma; Follicular lymphoma; Bladder cancer; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase I/II Lymphoma; Multiple myeloma
  • No development reported B cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 23 Oct 2017 Mundipharma completes a phase I/II trial in Peripheral T-cell lymphoma (second-line therapy or greater) in Japan, before October 2017 (NCT02013362)
  • 03 Jul 2017 Registered for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (IV)
  • 19 Jun 2017 Interim adverse events data from a phase I/II trial in Lymphoma released by Spectrum Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top